Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

被引:0
|
作者
Wu, Yuanlin [1 ]
Yu, Guangmao [1 ]
Jin, Ketao [2 ]
Qian, Jun [3 ]
机构
[1] Shaoxing Peoples Hosp, Dept Thorac Surg, Shaoxing, Zhejiang, Peoples R China
[2] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, Dept Gastrointestinal Colorectal & Anal Surg, Hangzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Xinchang Peoples Hosp, Affiliated Xinchang Hosp, Dept Colorectal Surg, Xinchang, Zhejiang, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
non-small cell lung cancer; immunotherapy; combination therapy; cancer vaccines; tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE-CHECKPOINT INHIBITOR; TYROSINE KINASE INHIBITORS; REGULATORY T-CELLS; PD-L1; EXPRESSION; ADVANCED NSCLC; OPEN-LABEL; PHASE-III; 1ST-LINE NIVOLUMAB; TARGETED THERAPIES;
D O I
10.3389/fimmu.2024.1349502
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying a substantial global health burden. While considerable progress has been made in recent years through the emergence of immunotherapy modalities, such as immune checkpoint inhibitors (ICIs), monotherapies often yield limited clinical outcomes. The rationale behind combining various immunotherapeutic or other anticancer agents, the mechanistic underpinnings, and the clinical evidence supporting their utilization is crucial in NSCLC therapy. Regarding the synergistic potential of combination immunotherapies, this study aims to provide insights to help the landscape of NSCLC treatment and improve clinical outcomes. In addition, this review article discusses the challenges and considerations of combination regimens, including toxicity management and patient selection.
引用
收藏
页数:31
相关论文
共 50 条
  • [1] The development of immunotherapies for non-small cell lung cancer
    Salgaller, ML
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (03) : 265 - 278
  • [2] Combining immunotherapies to treat non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (07) : 621 - 634
  • [3] Combination chemotherapy in the treatment of inoperable non-small cell lung cancer
    Rutherford, RM
    Azher, T
    Gilmartin, JJ
    IRISH JOURNAL OF MEDICAL SCIENCE, 2002, 171 (04) : 193 - 196
  • [4] Combination chemotherapy in the treatment of inoperable non-small cell lung cancer
    R. M. Rutherford
    T. Azher
    J. J. Gilmartin
    Irish Journal of Medical Science, 2002, 171 : 193 - 196
  • [5] Pemetrexed combination therapy in the treatment of non-small cell lung cancer
    Rosell, R
    Crinó, L
    SEMINARS IN ONCOLOGY, 2002, 29 (02) : 23 - 29
  • [6] Combination Immunotherapy in Non-small Cell Lung Cancer
    Melina E. Marmarelis
    Charu Aggarwal
    Current Oncology Reports, 2018, 20
  • [7] Combination Immunotherapy in Non-small Cell Lung Cancer
    Marmarelis, Melina E.
    Aggarwal, Charu
    CURRENT ONCOLOGY REPORTS, 2018, 20 (07)
  • [8] Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer
    Adjei, AA
    Argiris, A
    Murren, JR
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 32 - 40
  • [9] Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer
    Li, Dong
    He, Song
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 14693 - 14700
  • [10] Treatment of non-small cell lung cancer
    Reinmuth, N.
    Heigener, D.
    Reck, M.
    INTERNIST, 2011, 52 (12): : 1414 - 1421